Great Point Partners’s Celldex Therapeutics CLDX Stock Holding History

Great Point Partners’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-53,632	Closed	-$405K	–	34
2018 Q2	$405K	Buy	+53,632	New	+$717K	0.06%	36

Other funds holding CLDX

KLP Enterprises Branford, Connecticut $1.97M AUM

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Great Point Partners's CLDX Position: Q3 2018 in Review

Great Point Partners sold out of Celldex Therapeutics (CLDX) in Q3 2018, closing a stake of 53,632 shares — an estimated $405K sold.

Great Point Partners first reported a position in CLDX in Q2 2018 and held it in 1 quarter. The position peaked at $405K in Q2 2018. 95 funds tracked by Wall St. Rank hold CLDX as of Q3 2018.

Great Point Partners reported no remaining Celldex Therapeutics position as of Q3 2018 after selling out during the quarter.
Great Point Partners sold 53,632 Celldex Therapeutics shares in Q3 2018, an estimated $405K.
Great Point Partners first reported a position in Celldex Therapeutics in Q2 2018 and held it in 1 quarter.
Great Point Partners's Celldex Therapeutics position peaked at $405K in Q2 2018.
95 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2018.

Based on Great Point Partners's 13F filing for Q3 2018, filed 14 Nov 2018.